Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell
When the FDA approved two gene therapies for sickle cell disease in December 2023, many drugmakers viewed it as the end of the story and shelved their programs for the condition. Yet three years on ...
Romesh Subramanian, Marrow Therapeutics CEO November 17, 2026 07:00 AM EST FinancingCell/Gene Tx Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell Ryan Cross Senior Science Correspondent When the FDA approved two gene therapies for sickle cell disease in December 2023, many drugmakers viewed it as the end of the story and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that